Chapter PDF
Ausgewählte Literatur
Abraham et al (2005) Drotrecogin alfa (activated) for adults with severe sepsis and low risk of death. N Engl J Med 353:1332–1341
Adams HA, Baumann G, Cascorbi I et al (2005) Empfehlungen zur Diagnostik und Therapie der Schockformen der IAG Schock der DIVI. Teil 5: Septischer Schock. Intensivmed 41:531–543
Alb M, Hirner S, Luecke T (2007) Critical illness Polyneuropathie und Criticall Illness Myopathy. Anästhesiol Intensivmed Notfallmed Schmerzmed 4:250–258
Alberti C, Brun-Buisson C, Buchardi H, Martin J, Goodman S et al (2002) Epidemiology of sepsis and infection in ICU patients from international multicentre cohort study. Intensive Care Med 28:108–121
Alejandria MM et al. (2002) Intravenous immunoglobuline for treating sepsis and septic shock. (Cochrane Review). The Cochrane Library, Issue 1, Oxford
American College of Chest Physicians/Society of Critical Care Medicine (ACCP/SCCM) Concensus Conference (1992) Definition for sepsis and multiple organ failure, and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20: 864–874
Angstwurm et al (2007) Selenium in Intensive Care: results of a prospective randomized, placebo-controlled, multicenter study in patients with severe systemic inflammatory response syndrome, sepsis and septic shock. Crit Care Med 35:118–126
Angus DC et al (2003) The RIRO concept: P is for predisposition. Crit Care 7:248–251
Annan D et al (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 288:862–871
Annane D, Briegel J, Keh D, Moreno R, Singer M, Sprung CL; The Corticus Study Coordinators (2003) Clinical equipoise remains for issues of adrenocorticotropic hormone administration, cortisol testing, and therapeutic use of hydrocortisone. Crit Care Med 8:2250–2251
Ananne et al (2002) Effect of treatment with low doses of hydrocortisone and fludrocortisones on mortality in patients with septic shock. JAMA 288:862–871
ARDS-Network (2000) Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. NEJM 342:1301–1308
Annane D, Vignon P, Renault A et al (2007) Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial. The Lancet 370:676–684
Bauer A, Bruegger D, Christ F (2005) Mikrozirkulatorisches Monitoring in der Sepsis. Anaesthesist 54:1163–1175
Bernard GR et al (2001) Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344:699–709
Bodmann KF et al. (2004) Antimikrobielle Therapie der Sepsis: Chemotherapie Journal 9: 3–23
Bodmann KF, Grabein B, und die Expertenkommission der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V (2010) Empfehlungen zur kalkulierten parenteralen Initialtherapie bakterieller Erkrankungen bei Erwachsenen. Update 2010. Chemother J 19:179–255
Bone RC et al (1987) A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 317:653–658
Briegel J et al (1999) Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-centre study. Crit Care Med 27:723–732
Brower RG et al. (2004) Higher versus lower positive end-expiratory pressures in patients with acute respiratory distress syndrome. NEJM 2004 351:327–336 (ALVEOLI-Trial)
Brunkhorst FM, Karzai W, Reinhart K (2002) Diagnostic approach to sepsis – state of the art. Zentralbl Chir 127:165–173
Brunkhorst FM (2004) Aktuelle Aspekte und Zukunft der Sepsisdiagnose. J Anästhesie Intensivbehandlung 2:16–17
Brunkhorst FM, Engel C, Bloos F et al. (2008) Intensive Insulin Therapy and Pentastarch Resuscitation in Severe Sepsis N Engl J Med 358:125–139 (VISEP-Studie)
Cohen J (2004) Diagnosis of sepsis: an evidence-based review. Crit Care Med 32:466–494
DeBacker D, Verdant C, Chierego M, Koch M, Gullo A, Vincent JL (2006) Effects of drotrecogin alfa activated on microcirculation alterations in patients with severe sepsis. Crit Care Med 34:1918–1924
Dellinger RP et al. (2013) Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012. Crit Care Med 41:580–637 oder ICM 39: 165–228 oder Online unter www.sccm.org/documents/scc-guidelines.pdf )
Dellinger RP (2003) Cardiovascular management of septic shock. CCM 31:94–6
Finfer S et al. (2009). Glucose Control in Critically Ill Patients. N Engl J Med 361:89–92 (NICE-SUGAR-Study)
Forceville et al. (2007) Effects of high dosis of selenium, as sodium selenit, in septic shock: a placebo-controlled, randomized, double-blind, phase II study. Crit Care 11:R 73
Garlund B (2006) Aktivated protein C (Xigris) treatment in sepsis: d drug in trouble. Acta Anaesthesiol Scand 50:525–529
Gattinoni L et al (2003) Sepsis: state of the art. Minerva Anesthesiol 69:539–554
Guidet et al. Crit Care 16 R94 und Annane Djilllali. 2nd Paris International conference on Intensive Care (CRYSTMASTrial)
Hartog CS, Reinhart K (2012) CRYSTMAS study adds to concerns about renal safety and increased mortality in sepsis patients. Crit Care 16:45–4
Harbarth et al (2001) Diagnostic value of procalcitonin, interleukin 6 and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 164:396–402
Hotchkiss RS (2003) The pathophysiology and treatment of sepsis. N Engl J Med 348:138–150
Judemann K et al (2011) Erworbene Muskelschwäche beim Kritisch Kranken. Anaesthesist 60:887–901
Keh D et al (2003) Immunologic and hemodynamic effects of »low-dose« hydrocortisone in septic shock: a doubleblind, randomized, placebo-controlled, crossover study. Am J Respir Crit Care Med 167:512–520
Klinzing S (2003) High dose vasopressin is not superior to norepinephrine in septic shock. CCM 31:264–6
Kox W et al (2000) Immunmodulatory therapies in sepsis. Int Care Med 26:124–128
Kumar et al. Early antimicrobial therapy in severe sepsis and septic shock. Curr Infect Dis Rep 12: 336–344
Levy et al (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. CCM 31:1250–1256
Lopez A et al (2004) Multiple-center, randomized, placebocontrolled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 32:21–30
Martin GS et al (2003) The Epidemiology of Sepsis in the United States from 1979 through 2000. New Engl J Med 348:1546–1554
Matot I, Sprung CL (2001) Definition of sepsis. Intensive Care Med 27:3–9
Meade MO et al. (2008) Ventilation strategy using low tidal volumes, recruitment maneuvers, and high positive end-expiratory pressure for acute lung injury and acute respiratory distresssyndrome: a randomized controlled trial. JAMA 299: 637–645
Müller-Werdan U, Buerke M, Christoph A et al (2006) Septische Kardiomyopathie. Intensivmed 43:486–497
Myburgh JA, Finfer S, Bellomo R et al. (2012) Hydroxyethyl Starch or Saline for Fluid Resuscitation in Intensive Care. N Engl J Med 367:1901–1911 (CHEST-Trial)
Nasraway SA (2003) The Problems and Challenges of Immunotherapy in Sepsis. Chest 123:451–459
Nguyen H (2011) Lactate in the critically ill patients: an outcome marker with the times. Crit Care 15:101–6
O’Brien A, Clapp L, Singer M (2002) Terlipressin for norepinephrin-resistant septic shock. The Lancet 359:1209–1210
Patel BM, Chittock DR, Russell JA, Walley KR (2002) Beneficial effects of shortterm vasopressin infusion during severe septic shock. Anesthesiology 96:576–582
Perel A et al (2007) Management of Sepsis. NEJM 356:1178–1182
Perner A, Haase N, Guttormsen AB et al. (2012) Hydroxyethyl Starch 130/0.42 versus Ringer's Acetate in Severe Sepsis. N Engl J Med 367:124–134 (6S-Trial)
Refresher C (2008) Aktuelles Wissen für Anästhesisten 34: 139–159
Reinhart K, Bloos F, Engel C, for the German Competence Network (2006) Hydroxyethylstarch and Ringer's lactate for fluid resuscitation in patients with severe sepsis – results from the VISEP-Study. Intensive Care Med 32(1):A81–8
Reinhart K, Brunkhorst F, Bone HG et al (2006) Diagnose und Therapie der Sepsis. Anaesthesist 55(S1):43–56
Reinhart K et al. Prävention Diagnose, Therapie und Nachsorge der Sepsis (2010) 1. Revision der S-2k-Leitlinien der Deutschen Sepsis-Gesellschaft e.V. (DSG) und der Deutschen interdisziplinären Vereinigung der Intensiv und Notfallmedizin (DIVI) Journal für Anästhesie und Intensivbehandlung II.2010: 22–59
Rivers E and the Early Goal-directed Therapy Collaborative Group (2001) Early goal-directed therapy in the treatment of severe sepsis and septic shock. New Engl J Med 354:1368–1377
Russell JA (2006) Drug therapy: Management of sepsis. N Engl J Med 355:1699–1713
Russell JA et al (2008) Vasopressin versus norepinephrine infusion in patients with septic shock. NEJM 358:877–887
Schortgen F et al (2001) Effects of hydroxyethyl starch and gelatine on renal function in severe sepsis: a multicentre randomised study. The Lancet 357:911–916
Seifert et al. (2007) Blutkulturdiagnostik Sepsis, Endokarditis, Katheterinfektionen, Teil 1. Urban Fischer, München
Sessler CN, Perry JC, Varney KL (2004) Management of severe sepsis and septic shock. Curr Opin Crit Care 10:354–363
SIC-Studie (selenase in intensive care) (2005) Deutscher Anästhesiecongress Pro & Contra-Sitzung: »Selensubstitution bei Sepsis?« München 16. April 2005
Sprung CL et al (2008) Hydrocortisone therapy for patients with septic shock. N Engl J Med 358:111–124
The International Sepsis Forum (2001) Guidelines for the management of severe sepsis and septic shock. Intensive Care Med 27(Suppl 1):S1–S134
Van de Berghe G et al (2001) Intensive insulin therapy in critically ill patients. New Engl J Med 345:1359–1367
Van de Berghe G et al (2003) Outcome benefit of intensive insulin therapy in the critically ill: Insulin dose versus glycaemic control. Crit Care Med 31:359–366
Warren BL et al (2001) High-dose antithrombin III in severe sepsis. A randomized controlled trial. JAMA 286:1869–1871
Weigand M, Bardenheuer H, Böttiger B (2003) Klinisches Management bei Patienten mit Sepsis. Anaesthesist 52:3–22
Welte T (2004) Sepsis management – antibiotic therapy. Dtsch Med Wochenschr 129:2609–2613
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Fresenius, M. (2014). SIRS, Sepsis und Multiorganversagen. In: Repetitorium Intensivmedizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-44933-8_24
Download citation
DOI: https://doi.org/10.1007/978-3-642-44933-8_24
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-44932-1
Online ISBN: 978-3-642-44933-8
eBook Packages: Medicine (German Language)